If female, patient is eligible to participate if she is not pregnant, not breast - feeding, and at least 1 of the following conditions: a. Not a woman of childbearing potential (WOCBP) b. A WOCBP who agrees to follow contraceptive guidance (agree to use an adequate method of contraception) starting 30 days prior to the administration of the first dose of study therapy and continuing through 4 months after the last study treatment. The effect of galinpepimut -S on the fetus is unknown. 10. Male patients of childbearing potential must agree to use an adequate method of contraception, starting with the first dose of study therapy through 4 months following the last study treatment. It is unknown whether galinpepimut -S affects the sperm, or could be transmitted to the patie nt’s partner during sexual activity. Informed Consent 11.